BUFFALO, N.Y., U.S.: University at Buffalo (UB) researchers have received part of a $1.5 million grant to investigate light therapy as a possible replacement for prescription opioids in treating oral mucositis, painful ulcers and swelling in the mouth, the common side effects of chemotherapy and radiation treatment for cancer.
The grant, funded by the National Institute of Dental and Craniofacial Research Small Business Innovation Research program, was awarded to Cleveland-based MuReva Phototherapy, a medical device startup, to further develop the light technology to treat oral mucositis. UB received $511,000 of the award to be used to determine the effectiveness of photobiomodulation therapy and will conduct research in collaboration with faculty from the departments of Radiation Oncology and Oral Oncology at Roswell Park Comprehensive Cancer Center in Buffalo.
“The current epidemic of opioids has impacted cancer care, especially for cancer pain relief. This treatment offers a simple, nondrug, noninvasive treatment approach to relieve pain and improve quality of life for cancer patients,” said Dr. Praveen Arany, assistant professor at the UB School of Dental Medicine. “The striking lab and clinical evidence for photobiomodulation treatments in supportive cancer care has demonstrated tremendous promise and is becoming popular,” Arany continued.
Oral mucositis is said to be the worst side effect of cancer treatment. According to the Centers for Disease Control and Prevention, the condition occurs in close to 40 percent of patients receiving chemotherapy and nearly 80 percent of patients receiving radiation therapy for cancer. In addition to pain and comprised ability to eat or swallow, it may slow down or delay treatment and, in severe cases, require hospitalization and feeding tubes. “Given these significant adverse effects on the quality of life in our patients, it is a high priority for us to find new and better ways to prevent or treat this condition,” said Dr. Mukund Seshadri, professor and chair of the Department of Oral Oncology at Roswell Park Comprehensive Cancer Center.
The previous technologies that used light treatment were not affordable for wider use and were not able to determine its proper dosage to reduce pain and stimulate healing in tissues damaged by cancer treatment. “MuReva’s innovative mouthpiece, which can be self-administered, simultaneously targets a much larger portion of the oral cavity and delivers a full treatment in 6 minutes or less. We believe this technology has the potential to revolutionize the treatment for oral mucositis and finally present a market-ready solution to this debilitating side effect,” said Vedang Kothari, President and CEO of MuReva Phototherapy.
Tags:
COLUMBUS, Ohio, USA: As previous laboratory studies have suggested that dietary administration of whole strawberries has substantial potential as a strategy...
“Faster, higher, stronger”—this motto certainly no longer applies only to the Olympic Games. How can certain tasks be performed even more precisely, ...
PUNE, India: According to the World Cancer Research Fund International, cancer of the oral cavity is one of the most common types of cancer worldwide, with ...
WEYBRIDGE, UK: Haleon, a British multinational consumer healthcare company, and the College of General Dentistry have recently conducted a survey that ...
JERUSALEM, Israel: It has been previously established that adults who have undergone cancer treatment may have dental anomalies. However, no research to ...
A free webinar on 19 June will offer participants an opportunity to learn about how to implement orthodontic treatment as a fundamental tool in the context...
KRIENS, Switzerland: Chlorhexidine digluconate (CHX) is considered the gold standard among oral antiseptics, but its use comes with a number of side ...
MORTSEL, Belgium: After two decades of practising dentistry, Dr Veronica Stahl became frustrated about the lack of consumer products that combat dental ...
PORTOVIEJO, Ecuador: The application of the concept of osseointegration revolutionised the treatment of edentulous patients. However, as applications ...
BUENOS AIRES, Argentina: Sunstar proudly announces the launch of Oral Cancer: Prevention and Patient Management, an FDI World Dental Federation chairside ...
Live webinar
Thu. 18 July 2024
8:00 pm EST (New York)
Live webinar
Tue. 6 August 2024
6:00 pm EST (New York)
Live webinar
Tue. 13 August 2024
7:00 pm EST (New York)
Live webinar
Wed. 14 August 2024
12:30 pm EST (New York)
Live webinar
Wed. 21 August 2024
9:00 am EST (New York)
Dr. Jim Lai DMD, MSc(Perio), EdD, FRCD(C)
Live webinar
Wed. 28 August 2024
8:00 pm EST (New York)
Live webinar
Mon. 2 September 2024
5:00 am EST (New York)
To post a reply please login or register